CD44 and hepatocellular carcinoma: This approach was applied with a nanobody (VHH) antibody fragment against glypican-3 (GPC3), which is a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan expressed in >75% of hepatocellular carcinoma (HCC)32.